View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
July 12, 2019updated 12 Jul 2022 12:28pm

US researchers study rucaparib in endometrial cancer patients

A research team at the University of Colorado Cancer Center (CU Cancer Center) in the US is set to lead a new clinical trial assessing poly (ADP-ribose) polymerase (PARP) inhibitor Rucaparib for the treatment of patients with endometrial cancer.

A research team at the University of Colorado Cancer Center (CU Cancer Center) in the US is set to lead a new clinical trial assessing poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib for the treatment of patients with endometrial cancer.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Researchers partnered with pharmaceutical company Clovis Oncology to develop the Phase II study.

CU Cancer Center will act as the primary trial site, with the University of Pennsylvania and Fox Chase Cancer Center also enrolling patients.

The study intends to assess the effectiveness of rucaparib as maintenance therapy in metastatic or recurrent endometrial cancer patients who have previously received chemotherapy.

Rucaparib holds US Food and Drug Administration (FDA) approval and has been evaluated for the treatment of other cancer types.

CU Cancer Center gynecologic oncology assistant professor Bradley Corr said: “Very basically, rucaparib, a PARP inhibitor, works by stopping cancer cells from repairing their DNA appropriately.

“Cancer cells can hijack the body’s system to repair their own DNA, which allows them to multiply. Without the ability to repair damaged DNA, the cancer cells eventually die.”

PARP inhibitors are commonly used to treat BRCA ovarian cancer patients.

Preclinical studies showed that patients who have a PTEN deficiency may respond to PARP inhibitors, with the PTEN mutation found in more than 80% of endometrial cancer patients.

Corr noted: “I believe that this clinical trial could be the foundation step to practice-changing therapy.

“There are currently no approved maintenance therapies in endometrial cancer, and if this trial demonstrates similar success rate to what we have seen in ovarian cancer, I believe this drug class could become a part of standard care for some patients.”

This Phase II trial is said to be the first to test a PARP inhibitor for endometrial cancer.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena